Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
- Mar 11, 2020- Fourth quarter revenue of $8.3 million, up 52% over the prior year
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today...
- Mar 02, 2020Expanded Intellectual Property Related to 2019 Acquisitions of Astero Bio and SAVSU Technologies
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced three new patents for bioproduction tools...
- Feb 12, 2020Q4 & FY2019 Earnings Conference Call on March 11th at 4:30 PM EST
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today...
- Dec 02, 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today...
- Nov 12, 2019Global leader in liquid nitrogen storage systems expected to support growth, diversify revenue and reduce evo® manufacturing costs
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today...
- Nov 12, 2019Third quarter revenue of $6.6 million, up 25% over the prior year
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today...
- Nov 07, 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that based on revenue...
- Oct 31, 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" or the "Company"), today announced that the...
- Oct 14, 2019Intellectual Property Portfolio Growing with Inventions by Acquired Companies
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced three new patents for inventions related...
- Sep 24, 2019BioLife's strategic acquisition strategy expanded to include co-investment with Casdin Capital to boost early stage company development and commercialization
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced a co-investment accelerator program with...
- Sep 16, 2019Leading Cell and Gene Therapy Companies are De-Risking Clinical Trial and Commercial Shipments by Using State of the Art Cloud-Connected Shippers and evo.is
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced several new customers have...
- Sep 03, 2019Pipeline and Clinical Trials Focused on Cancers and Genetic Disorders
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that Mustang Bio, Inc....
- Aug 28, 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the hiring of two key...
- Aug 12, 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today...
- Aug 08, 2019- Record quarterly revenue of $6.7 million, up 29% over the prior year
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today...
- Aug 08, 2019evo® Cold Chain Management System, Designed for High-Value, Temperature-Sensitive Biologics, Used for Initial Shipments by 50 Cell & Gene Therapy Companies
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a...
- Jul 31, 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the...
- Jul 30, 2019Reduced in-transit shipping damage, Extended dynamic thermal performance and Predictive Analytics in Next Generation Dry Vapor Liquid Nitrogen Shippers
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a...
- Jul 23, 2019evo® Cold Chain Management System and LifeGuard Same Day Service Reduce Risks for High-Value, Temperature-Sensitive Biologic Drugs
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a...
- Jul 08, 2019Acquisition further strengthens portfolio of best in class, proprietary enabling solutions for cell and gene therapy companies
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices for cell and gene therapies,...
- Jun 10, 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for...
- May 30, 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for...
- May 29, 2019Cloud-Connected, Smart Shippers and evo.is Real-Time Visibility Platform Improve Quality of Transportation and Delivery of Lifesaving Therapies
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for...
- May 09, 2019- Revenue Increased 51% to a Record $5.8 million
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices...
- May 02, 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the...
- Apr 02, 2019Gains products that automate the thawing process for high-value biologic therapies
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife") today announced that it has closed the previously announced transaction for the acquisition of Astero Bio Corporation ("Astero"), an innovator in...
- Mar 14, 2019Revenue Increased 79% for the Year to $19.7 Million
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary cell and tissue hypothermic storage and cryopreservation freeze media, today...
- Mar 14, 2019Gains products that automate the thawing process for high-value biologic therapies
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife") today announced that it has entered into an agreement to acquire Astero Bio Corporation ("Astero"), a privately-held innovator in the design,...
- Mar 04, 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the...
- Feb 19, 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today announced that...
- Jan 22, 2019FDA Cites Increases in IND Submissions and Anticipated Product Approvals that could benefit BioLife Solutions
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, expects to benefit from new...
- Nov 27, 2018Redemption eliminates annual cash dividend payment
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, ("BioLife" or the "Company"),...
- Nov 13, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today announced that...
- Nov 08, 2018Revenue increases 79% to a record $5.3 million; achieves net income of $1.2 million
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today reported...
- Nov 01, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that the...
- Oct 01, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- Sep 05, 2018Agreement Includes 18-Month Option to Acquire all SAVSU Outstanding Shares
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading supplier of proprietary biopreservation media products for cell and gene therapies, today announced that it has increased its...
- Aug 22, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading supplier of proprietary biopreservation media products for cell and gene therapies, today announced that CEO Mike Rice, accompanied...
- Aug 09, 2018Revenue increases 102% to $5.2 million. Net income of $1.0 million achieved
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- Aug 09, 2018M&A Activities to Focus on Cell and Gene Manufacturing Tools
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that...
- Aug 06, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that...
- Aug 02, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that the...
- Jul 09, 2018Investment Firm to Purchase Shares from Existing Holders
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that two...
- Jul 02, 2018Full Year 2018 Revenue Guidance Increased
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- Jun 11, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, today announced that it is set to join the Russell...
- May 29, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, today announced Michael Rice, CEO, and Roderick de...
- May 17, 2018Redemption reduces annual cash dividend payment by $106,000
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, ("BioLife" or the "Company"), today announced it has...
- May 16, 2018SAVSU Realizing Expanded evo® Product Adoption by Leading Specialty Logistics Providers and Cell Therapy Manufacturers
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, ("BioLife" or the "Company"), today announced a $1...
- May 10, 201861% Revenue Growth at $3.8 Million
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- May 03, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the...
- Apr 30, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today...
- Apr 09, 2018Investment Firm to Purchase Shares from Existing Holder
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that...
- Apr 02, 20182018 Revenue Guidance Revised Upward
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- Mar 26, 201812 Additional Pending Patent Applications Submitted for evo® Smart Shippers, Liquid Nitrogen Dry Vapor Shippers and Cold Chain SaaS Application
BioLife Solutions and SAVSU Technologies to be Awarded Second Patent for Next Generation Cold Chain Technologies Designed for Cell and Gene Therapies 12 Additional Pending Patent Applications...
- Mar 13, 2018Published in Springer Nature Journal Laboratory Investigation; Superior Performance Over Traditional "Home Brew" Cryopreservation Formula
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- Mar 08, 2018Revenue Increased 39% for the Quarter and 34% for the Year
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- Mar 01, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the...
- Feb 13, 2018
Private Labeled CryoStor® Cell Freeze Media and HypoThermosol® Cell and Tissue Storage and Shipping Media Distributed to Worldwide Biotech Research MarketBioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media ("BioLife" or the "Company"), today announced that it...
- Jan 23, 2018World Courier Integrates SAVSU Technologies' Next Generation of Dry Shippers with its Global Cell and Gene Therapy Logistics Platform
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media ("BioLife" or the "Company"), today announced that its...
- Jan 18, 201813 Additional Pending Patent Applications Submitted for evo Smart Shippers, Liquid Nitrogen Dry Vapor Shippers (DVS) and Cold Chain SaaS Application
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and...
- Jan 16, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today...
- Jan 04, 2018Q4 2017 Preliminary Revenue Reaches Record $3.1 Million, up 39% over Q4 2016
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical-grade cell and tissue hypothermic storage and cryopreservation freeze...
- Dec 13, 2017
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media ("BioLife" or the "Company"), today announced that it...
- Nov 29, 2017
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- Nov 09, 2017Revenue Increased 39% Over Prior Year
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
- Nov 02, 2017
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the...
- Oct 31, 2017CryoStor® Cell Freeze Media and evo® Smart Shipper Embedded in Trials Using Treg Cells for Diabetes, Lupus, Pemphigus, and Organ Transplantation
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and...
- Oct 30, 2017
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today...
- Oct 19, 2017Each Yescarta Dose is Frozen in Proprietary CryoStor® Freeze Media to Maintain CAR T-Cell Viability and Enable Worldwide Distribution
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media...
- Oct 18, 2017
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today...
- Sep 19, 2017Off the Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media...
- Sep 07, 2017
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media...
- Aug 10, 201729% Year Over Year Revenue Growth
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media...
- Aug 03, 2017
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the...
- Jul 31, 2017Proprietary Clinical Grade Cell Freeze Media Enables Long-Term Storage and Distribution of Engineered Cell-Based Therapies
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media...
- Jul 13, 2017Korean Approval Received by Kolon Life Science, TissueGene's Exclusive Licensee
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading supplier of pre-formulated, clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), today announced...
- Jul 05, 2017
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media...
- Jun 14, 2017Proprietary Clinical Grade Cell Freeze Media Enables Long-Term Storage and Distribution of T-Cells
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- May 11, 201728% Year Over Year Revenue Growth
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media...
- May 04, 2017
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the...
- Mar 09, 2017
Record Biopreservation Media Revenue, 28% Growth Over 2015BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media...
- Mar 02, 2017
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media...
- Jan 12, 20172017 Guidance Provided
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media...
- Jan 10, 2017Maturity Date Extension and Full Cash Repayment by June 2022
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media...
- Jan 03, 2017Consolidation of Cold Chain Technologies Enables External Investment in evo™ Smart Shipper and biologistex SaaS Opportunity
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- Dec 20, 2016
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- Nov 10, 2016Biopreservation Media Revenue Grew 31% Over 2015
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- Nov 03, 2016
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal...
- Oct 26, 2016CryoStor® Cell Freeze Media, evo™ Smart Shipper and BioStore™ III Cryo LN2 Storage System Enable Improved Cell Viability and Faster Cell Recovery
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- Sep 15, 2016
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- Aug 24, 2016Approval to Market Invossa™ Filed with Korean Ministry of Food and Drug Safety
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- Aug 11, 2016Biopreservation Media Revenue Grew 39% Over 2015
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- Aug 10, 2016
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- Aug 03, 2016
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal...
- Jul 18, 2016
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- Jul 11, 2016
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- May 19, 2016evo™ Smart Shipper, biologistex™ SaaS and MNX's Managed Logistics Service Provide Best-in-Class Solution for Shipping Apheresis Starting Material for Manufactured Cell Product
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- May 18, 2016Proven C Level Sales Performance in First in Class Medical Devices, Software, Healthcare Practice Management
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- May 12, 2016$4 Million Credit Facility from Largest Shareholder Provides Additional Operating Capital to Fund biologistex™ Product Offering
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related
- May 06, 2016
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal...
